Elex Biotech Inc is a drug discovery and development company focused on first-in-class NCEs for the treatment of arrhythmia and heart failure. Using rational drug design and an internally generated SAR database, the Company has generated ~200 NCEs that stabilize mutant or dysfunctional RyR2, the Ca2+ release channel that regulates heart muscle contractions. Certain arrhythmias and heart failure share a common defect in Ca2+ handling resulting from RyR2 dysfunction that is addressed by Elex Biotech’s compounds. Elex Biotech has a lead and backup compounds with in vivo proof of concept in animal models of catecholaminergic polymorphic ventricular tachycardia (CPVT), an orphan disease estimated to cause 15% of unexplained sudden cardiac death in apparently healthy young people. Elex Biotech has been funded to date by ~$2M in NHLBI STTR grants and, in June 2019, received an NHLBI Phase IIB Small Market Award of ~$3M to advance its lead candidate through IND-enabling studies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Oral small molecule for treatment of arrhythmia in CPVT, an orphan disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):